The Medical Letter on Drugs and Therapeutics
FROM
ISSUE1646
ISSUE1646
March 21, 2022
Inclisiran (Leqvio) for LDL-Cholesterol Lowering
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Inclisiran (Leqvio) for LDL-Cholesterol Lowering
March 21, 2022 (Issue: 1646)
The FDA has approved inclisiran (Leqvio – Novartis),
a small interfering RNA (siRNA) directed to proprotein
convertase subtilisin/kexin type 9 (PCSK9) mRNA,
as an adjunct to diet and maximally tolerated statin
therapy for subcutaneous (SC)...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.